{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:36:57Z","timestamp":1788820617697,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Invasive fungal infections (IFIs) are life-threatening complications in immunocompromised patients, particularly those with hematologic malignancies or undergoing transplantation. Despite advances in diagnostic methods and antifungal therapy, IFI-related mortality remains unacceptably high. Evidence from Latin America is scarce, limiting the understanding of regional epidemiology and outcomes.\u00a0Our work aimed to analyze the epidemiological and clinical profiles of pediatric hemato-oncologic patients diagnosed with proven IFIs. We conducted a retrospective, cross-sectional study by reviewing medical records of patients diagnosed with proven IFIs according to the 2020 criteria of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group, at the Hospital Universitario \u201cDr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d in northeast Mexico, between 2018 and 2024. Statistical analysis included descriptive and inferential methods. A p-value\u2009&lt;\u20090.05 was considered statistically significant.\u00a0Thirty-three patients were included (mean age 6 years; 54.5% male). Most (91%) were classified as high risk for IFIs, and acute lymphoblastic leukemia was the most frequent underlying malignancy (72.7%). Mold infections accounted for 69.7% of cases, mainly\n                    <jats:italic>Aspergillus spp.<\/jats:italic>\n                    and\n                    <jats:italic>Fusarium spp.<\/jats:italic>\n                    , while\n                    <jats:italic>Candida tropicalis<\/jats:italic>\n                    was the most common yeast. The sinonasal region was the predominant site of mold disease. Prophylaxis was administered in 69.7% of patients, most commonly with itraconazole. Amphotericin B was the primary therapeutic agent, alone or in combination with voriconazole, and 42.4% required surgical intervention. Overall mortality was 21.2%, higher in yeast infections (30%) compared with molds (17.4%). Intensive care unit admission was the only independent predictor of death (OR 35.4;\n                    <jats:italic>p\u2009=<\/jats:italic>\n                    \u20090.019).\u00a0In pediatric hemato-oncologic patients, IFIs were predominantly associated with acute lymphoblastic leukemia, neutropenia, and induction chemotherapy. Mold infections accounted for most cases, and mortality remained high despite prophylaxis. These findings provide novel data from Latin America, where studies on pediatric IFIs are limited, and underscore the need for improved diagnostic and preventive strategies in high-risk populations.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06655-w","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T04:34:24Z","timestamp":1761280464000},"page":"6021-6031","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Epidemiology and clinical characterization of invasive fungal infections in pediatric hemato-oncologic patients at a tertiary referral center in Northeastern Mexico"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3181-7983","authenticated-orcid":false,"given":"Denisse Natalie","family":"Vaquera-Aparicio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4270-2687","authenticated-orcid":false,"given":"Jos\u00e9 Iv\u00e1n","family":"Castillo-Bejarano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4057-9526","authenticated-orcid":false,"given":"Abiel Homero","family":"Mascare\u00f1as-de-los-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogelio de Jesus","family":"Trevi\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2713-2498","authenticated-orcid":false,"given":"Paul Santiago","family":"Arcos-Viscarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8159-8299","authenticated-orcid":false,"given":"Marcela Lizeth","family":"Morales-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5035-0268","authenticated-orcid":false,"given":"Ana Sof\u00eda","family":"Guerrero-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"6655_CR1","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1093\/cid\/ciaa1751","volume":"72","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Azoulay E, Kullberg B-J, Ruhnke M, Shoham S, Vazquez J et al (2021) EORTC\/MSGERC definitions of invasive fungal diseases: summary of activities of the intensive care unit working group. Clin Infect Dis 72:S121\u2013S127. https:\/\/doi.org\/10.1093\/cid\/ciaa1751","journal-title":"Clin Infect Dis"},{"issue":"6","key":"6655_CR2","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE et al (2020) Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis 71(6):1367\u20131376. https:\/\/doi.org\/10.1093\/cid\/ciz1008","journal-title":"Clin Infect Dis"},{"key":"6655_CR3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/myc.13148","volume":"63","author":"JD Jenks","year":"2020","unstructured":"Jenks JD, Cornely OA, Chen SC-A, Thompson GR 3rd, Hoenigl M (2020) Breakthrough invasive fungal infections: who is at risk? Mycoses 63:1021\u20131032. https:\/\/doi.org\/10.1111\/myc.13148","journal-title":"Mycoses"},{"key":"6655_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12929-023-00926-2","volume":"30","author":"W Fang","year":"2023","unstructured":"Fang W, Wu J, Cheng M, Zhu X, Du M, Chen C et al (2023) Diagnosis of invasive fungal infections: challenges and recent developments. J Biomed Sci 30:42. https:\/\/doi.org\/10.1186\/s12929-023-00926-2","journal-title":"J Biomed Sci"},{"key":"6655_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/2110-5820-2-6","volume":"2","author":"O Brissaud","year":"2012","unstructured":"Brissaud O, Guichoux J, Harambat J, Tandonnet O, Zaoutis T (2012) Invasive fungal disease in PICU: epidemiology and risk factors. Ann Intensive Care 2:6. https:\/\/doi.org\/10.1186\/2110-5820-2-6","journal-title":"Ann Intensive Care"},{"key":"6655_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00277-017-3196-2","volume":"97","author":"SC Mellinghoff","year":"2018","unstructured":"Mellinghoff SC, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M et al (2018) Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the infectious diseases working party (AGIHO) of the German society for haematology and medical oncology (DGHO). Ann Hematol 97:197\u2013207. https:\/\/doi.org\/10.1007\/s00277-017-3196-2","journal-title":"Ann Hematol"},{"key":"6655_CR7","doi-asserted-by":"publisher","DOI":"10.1177\/20499361241282835","volume":"11","author":"J Salmanton-Garc\u00eda","year":"2024","unstructured":"Salmanton-Garc\u00eda J (2024) Update on invasive fungal infections: emerging trends in the incidence of fungal infections in immunosuppressed patients and associated conditions. Ther Adv Infect Dis 11:20499361241282835. https:\/\/doi.org\/10.1177\/20499361241282835","journal-title":"Ther Adv Infect Dis"},{"key":"6655_CR8","doi-asserted-by":"publisher","first-page":"4419","DOI":"10.1128\/JCM.42.10.4419-4431.2004","volume":"42","author":"MA Pfaller","year":"2004","unstructured":"Pfaller MA, Diekema DJ (2004) Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 42:4419\u20134431. https:\/\/doi.org\/10.1128\/JCM.42.10.4419-4431.2004","journal-title":"J Clin Microbiol"},{"issue":"1","key":"6655_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01123-6","volume":"7","author":"M-H Tsai","year":"2017","unstructured":"Tsai M-H, Hsu J-F, Chu S-M, Chang P-J, Lai M-Y, Wu I-H et al (2017) Clinical and microbiological characteristics, and impact of therapeutic strategies on the outcomes of children with candidemia. Sci Rep 7(1):1083. https:\/\/doi.org\/10.1038\/s41598-017-01123-6","journal-title":"Sci Rep"},{"issue":"9","key":"6655_CR10","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","volume":"49","author":"M Morrell","year":"2005","unstructured":"Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49(9):3640\u20133645. https:\/\/doi.org\/10.1128\/AAC.49.9.3640-3645.2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"6655_CR11","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3390\/jof811114612","volume":"8","author":"SS Kanj","year":"2022","unstructured":"Kanj SS, Omrani AS, Al-Abdely HM, Subhi A, Fakih RE, Abosoudah I et al (2022) Survival outcome of empirical antifungal therapy and the value of early initiation: A review of the last decade. J Fungi (Basel) [Internet] 8(11):1146 Disponible en:. https:\/\/doi.org\/10.3390\/jof811114612","journal-title":"J Fungi (Basel) [Internet]"},{"key":"6655_CR12","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1345\/aph.1r775","volume":"47","author":"VA Bernardo","year":"2013","unstructured":"Bernardo VA, Cross SJ, Crews KR, Flynn PM, Hoffman JM, Knapp KM et al (2013) Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer. Ann Pharmacother 47:976\u2013983. https:\/\/doi.org\/10.1345\/aph.1r775","journal-title":"Ann Pharmacother"},{"key":"6655_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40272-020-00379-2","volume":"22","author":"KJ Downes","year":"2020","unstructured":"Downes KJ, Fisher BT, Zane NR (2020) Administration and dosing of systemic antifungal agents in pediatric patients. Paediatr Drugs 22:165\u2013188. https:\/\/doi.org\/10.1007\/s40272-020-00379-2","journal-title":"Paediatr Drugs"},{"key":"6655_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jof4040127","volume":"4","author":"PL White","year":"2018","unstructured":"White PL, Price JS, Backx M (2018) Therapy and management of Pneumocystis jirovecii infection. J Fungi 4:127. https:\/\/doi.org\/10.3390\/jof4040127","journal-title":"J Fungi"},{"key":"6655_CR15","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1093\/jac\/dkw157","volume":"71","author":"J Maertens","year":"2016","unstructured":"Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A et al (2016) ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 71:2397\u20132404. https:\/\/doi.org\/10.1093\/jac\/dkw157","journal-title":"J Antimicrob Chemother"},{"key":"6655_CR16","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s11912-022-01192-5","volume":"24","author":"S Villeneuve","year":"2022","unstructured":"Villeneuve S, Aftandilian C (2022) Neutropenia and infection prophylaxis in childhood cancer. Curr Oncol Rep 24:671\u2013686. https:\/\/doi.org\/10.1007\/s11912-022-01192-5","journal-title":"Curr Oncol Rep"},{"key":"6655_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.riam.2013.05.011","volume":"30","author":"ME Santolaya","year":"2013","unstructured":"Santolaya ME, de Queiroz Telles F, Alvarado Matute T, Colombo AL, Zurita J, Tiraboschi IN et al (2013) Recomendaciones Para El Manejo de La candidemia En ni\u00f1os En Am\u00e9rica Latina. Rev Iberoam Micol 30:171\u2013178. https:\/\/doi.org\/10.1016\/j.riam.2013.05.011","journal-title":"Rev Iberoam Micol"},{"issue":"6","key":"6655_CR18","doi-asserted-by":"publisher","first-page":"857","DOI":"10.4067\/S0716-10182021000600857","volume":"38","author":"ME Santolaya","year":"2021","unstructured":"Santolaya ME, \u00c1lvarez AM, Avil\u00e9s CL, Becker A, Cofr\u00e9 J, Escobar A et al (2021) Management of episodes of febrile neutropenia in children with cancer. Consensus of the Latin American society of pediatric infectious diseases 2021. Rev Chil Infectol 38(6):857\u2013909. https:\/\/doi.org\/10.4067\/S0716-10182021000600857","journal-title":"Rev Chil Infectol"},{"key":"6655_CR19","first-page":"1068","volume":"91","author":"L Pagano","year":"2006","unstructured":"Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B et al (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91:1068\u20131075","journal-title":"Haematologica"},{"issue":"4","key":"6655_CR20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.4067\/s0716-10182023000400360","volume":"40","author":"V Guti\u00e9rrez","year":"2023","unstructured":"Guti\u00e9rrez V, Contardo V, Maza V, de la Claverie X, Salgado C, Zubieta M (2023) Infecciones f\u00fangicas Invasoras En ni\u00f1os Con c\u00e1ncer y portadores de aplasia medular Severa En Nueve hospitales de La red PINDA, Chile. 2016\u20132020. Rev Chilena Infectol 40(4):360\u2013369. https:\/\/doi.org\/10.4067\/s0716-10182023000400360","journal-title":"Rev Chilena Infectol"},{"issue":"3","key":"6655_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/jpids\/pix030","volume":"7","author":"BT Fisher","year":"2018","unstructured":"Fisher BT, Robinson PD, Lehrnbecher T, Steinbach WJ, Zaoutis TE, Phillips B et al (2018) Risk factors for invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review. J Pediatr Infect Dis Soc 7(3):191\u2013198. https:\/\/doi.org\/10.1093\/jpids\/pix030","journal-title":"J Pediatr Infect Dis Soc"},{"key":"6655_CR22","first-page":"159","volume":"48","author":"P Phikulsod","year":"2017","unstructured":"Phikulsod P, Suwannawiboon B, Chayakulkeeree M (2017) Invasive fungal infection among febrile patients with chemotherapy-induced neutropenia in Thailand. Southeast Asian J Trop Med Public Health 48:159\u2013169","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"6655_CR23","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1097\/MPH.0000000000002723","volume":"45","author":"G Avcu","year":"2023","unstructured":"Avcu G, Karadas N, Goktepe SO, Bal ZS, Metin DY, Polat SH et al (2023) Invasive fungal infections in children with acute myeloid leukemia: a single-center experience over 19 years. J Pediatr Hematol Oncol 45:392\u2013397. https:\/\/doi.org\/10.1097\/MPH.0000000000002723","journal-title":"J Pediatr Hematol Oncol"},{"key":"6655_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29275","volume":"68","author":"DK Yeoh","year":"2021","unstructured":"Yeoh DK, Moore AS, Kotecha RS, Bartlett AW, Ryan AL, Cann MP et al (2021) Invasive fungal disease in children with acute myeloid leukaemia: an Australian multicentre 10-year review. Pediatr Blood Cancer 68:e29275. https:\/\/doi.org\/10.1002\/pbc.29275","journal-title":"Pediatr Blood Cancer"},{"key":"6655_CR25","doi-asserted-by":"publisher","first-page":"e653","DOI":"10.1097\/MPH.0000000000002297","volume":"44","author":"M Yigit","year":"2022","unstructured":"Yigit M, Arman Bilir \u00d6, Kanik Y\u00fcksek S, Ka\u00e7ar D, \u00d6zbek NY, Yarali HN (2022) Antifungal therapy in pediatric acute lymphoblastic leukemia: a single-center experience: a single-center experience. J Pediatr Hematol Oncol 44:e653\u2013e657. https:\/\/doi.org\/10.1097\/MPH.0000000000002297","journal-title":"J Pediatr Hematol Oncol"},{"key":"6655_CR26","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1097\/01.inf.0000220256.69385.2e","volume":"25","author":"E Castagnola","year":"2006","unstructured":"Castagnola E, Cesaro S, Giacchino M, Livadiotti S, Tucci F, Zanazzo G et al (2006) Fungal infections in children with cancer: a prospective, multicenter surveillance study: A prospective, multicenter surveillance study. Pediatr Infect Dis J 25:634\u2013639. https:\/\/doi.org\/10.1097\/01.inf.0000220256.69385.2e","journal-title":"Pediatr Infect Dis J"},{"issue":"9398","key":"6655_CR27","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/S0140-6736(03)14904-5","volume":"362","author":"MS Lionakis","year":"2003","unstructured":"Lionakis MS, Kontoyiannis DP (2003) Glucocorticoids and invasive fungal infections. Lancet 362(9398):1828\u20131838","journal-title":"Lancet"},{"issue":"8","key":"6655_CR28","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/jac\/dks155","volume":"67","author":"M Hoenigl","year":"2012","unstructured":"Hoenigl M, Strenger V, Buzina W, Valentin T, Koidl C, Wolfler A et al (2012) European organization for the research and treatment of Cancer\/Mycoses study group (EORTC\/MSG) host factors and invasive fungal infections in patients with haematological malignancies. J Antimicrob Chemother 67(8):2029\u20132033","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"6655_CR29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/sj.bmt.1704543","volume":"34","author":"K Thursky","year":"2004","unstructured":"Thursky K, Byrnes G, Grigg A, Szer J, Slavin M (2004) Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 34(2):115\u2013121","journal-title":"Bone Marrow Transplant"},{"key":"6655_CR30","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3389\/fmicb.2019.00681","volume":"10","author":"T Lehrnbecher","year":"2019","unstructured":"Lehrnbecher T, Sch\u00f6ning S, Poyer F, Georg J, Becker A, Gordon K et al (2019) Incidence and outcome of invasive fungal diseases in children with hematological malignancies and\/or allogeneic hematopoietic stem cell transplantation: results of a prospective multicenter study. Front Microbiol 10:681. https:\/\/doi.org\/10.3389\/fmicb.2019.00681","journal-title":"Front Microbiol"},{"key":"6655_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/pbc.23415","volume":"59","author":"CC Dvorak","year":"2012","unstructured":"Dvorak CC, Fisher BT, Sung L, Steinbach WJ, Nieder M, Alexander S et al (2012) Antifungal prophylaxis in pediatric hematology\/oncology: new choices & new data. Pediatr Blood Cancer 59:21\u201326. https:\/\/doi.org\/10.1002\/pbc.23415","journal-title":"Pediatr Blood Cancer"},{"key":"6655_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.riam.2021.04.005","volume":"38","author":"M Gonz\u00e1lez-Vicent","year":"2021","unstructured":"Gonz\u00e1lez-Vicent M, Ramos-Amador JT (2021) La infecci\u00f3n f\u00fangica En El Paciente pedi\u00e1trico inmunodeprimido. Rev Iberoam Micol 38:75\u201383. https:\/\/doi.org\/10.1016\/j.riam.2021.04.005","journal-title":"Rev Iberoam Micol"},{"issue":"8","key":"6655_CR33","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/jac\/dkad143","volume":"78","author":"J Stemler","year":"2023","unstructured":"Stemler J, Mellinghoff SC, Khodamoradi Y, Teschner D, Cornely OA, Ruhnke M et al (2023) Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update. J Antimicrob Chemother 78(8):1813\u20131829. https:\/\/doi.org\/10.1093\/jac\/dkad143","journal-title":"J Antimicrob Chemother"},{"key":"6655_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1093\/cid\/ciae203","volume":"79","author":"C-A Boutin","year":"2024","unstructured":"Boutin C-A, Durocher F, Beauchemin S, Ziegler D, Abou Chakra CN, Dufresne SF (2024) Breakthrough invasive fungal infections in patients with high-risk hematological disorders receiving voriconazole and posaconazole prophylaxis: a systematic review. Clin Infect Dis 79:151\u2013160. https:\/\/doi.org\/10.1093\/cid\/ciae203","journal-title":"Clin Infect Dis"},{"key":"6655_CR35","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.20.00158","volume":"38","author":"T Lehrnbecher","year":"2020","unstructured":"Lehrnbecher T, Fisher BT, Phillips B, Beauchemin M, Carlesse F, Castagnola E et al (2020) Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. J Clin Oncol 38:3205\u20133216. https:\/\/doi.org\/10.1200\/JCO.20.00158","journal-title":"J Clin Oncol"},{"key":"6655_CR36","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000003942","volume":"42","author":"I Kaur","year":"2023","unstructured":"Kaur I, De St Maurice A (2023) Catheter-related Aspergillus fungemia: case report and literature review. Pediatr Infect Dis J 42:e308\u2013e311. https:\/\/doi.org\/10.1097\/INF.0000000000003942","journal-title":"Pediatr Infect Dis J"},{"key":"6655_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.4274\/tjh.galenos.2021.2021.0203","volume":"39","author":"M Sezgin Evim","year":"2022","unstructured":"Sezgin Evim M, T\u00fcfek\u00e7i \u00d6, Baytan B, \u00d6ren H, \u00c7elebi S, Ener B et al (2022) Invasive fungal infections in children with leukemia: clinical features and prognosis. Turk J Hematol 39:94\u2013102. https:\/\/doi.org\/10.4274\/tjh.galenos.2021.2021.0203","journal-title":"Turk J Hematol"},{"key":"6655_CR38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jpeds.2013.10.021","volume":"164","author":"D Caselli","year":"2014","unstructured":"Caselli D, Petris MG, Rondelli R, Carraro F, Colombini A, Muggeo P et al (2014) Single-day trimethoprim\/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer. J Pediatr 164:389\u201392.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2013.10.021","journal-title":"J Pediatr"},{"key":"6655_CR39","doi-asserted-by":"publisher","first-page":"647","DOI":"10.20471\/acc.2022.61.04.11","volume":"61","author":"D Buljan","year":"2022","unstructured":"Buljan D, Kranj\u010dec I, Pavi\u0107 I, Krnjai\u0107 P, \u0160alig S, Jakovljevi\u0107 G et al (2022) Invasive fungal infections in children treated for hematologic malignancies - a five-year single center experience. Acta Clin Croat 61:647\u2013654. https:\/\/doi.org\/10.20471\/acc.2022.61.04.11","journal-title":"Acta Clin Croat"},{"key":"6655_CR40","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/ejh.12910","volume":"99","author":"S Cesaro","year":"2017","unstructured":"Cesaro S, Tridello G, Castagnola E, Calore E, Carraro F, Mariotti I et al (2017) Retrospective study on the incidence and outcome of proven and probable invasive fungal infections in high-risk pediatric onco-hematological patients. Eur J Haematol 99:240\u2013248. https:\/\/doi.org\/10.1111\/ejh.12910","journal-title":"Eur J Haematol"},{"key":"6655_CR41","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s12879-023-08314-9","volume":"23","author":"L Calle-Miguel","year":"2023","unstructured":"Calle-Miguel L, Garrido-Colino C, Santiago-Garc\u00eda B, Moreno Santos MP, Gonzalo Pascual H, Ponce Salas B et al (2023) Changes in the epidemiology of invasive fungal disease in a pediatric hematology and oncology unit: the relevance of breakthrough infections. BMC Infect Dis 23:348. https:\/\/doi.org\/10.1186\/s12879-023-08314-9","journal-title":"BMC Infect Dis"},{"issue":"1","key":"6655_CR42","doi-asserted-by":"publisher","first-page":"e2021039","DOI":"10.4084\/MJHID.2021.039","volume":"13","author":"S Supatharawanich","year":"2021","unstructured":"Supatharawanich S, Narkbunnam N, Vathana N, Takpradit C, Phuakpet K, Pongtanakul B et al (2021) Invasive fungal diseases in children with acute leukemia and severe aplastic anemia: IFI in children with acute leukemia and SAA. Mediterr J Hematol Infect Dis [Internet] 13(1):e2021039 Disponible en:. https:\/\/doi.org\/10.4084\/MJHID.2021.039","journal-title":"Mediterr J Hematol Infect Dis [Internet]"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06655-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06655-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06655-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T02:31:24Z","timestamp":1764729084000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06655-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["6655"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06655-w","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was retrospective and used anonymized data; therefore, approval and informed consent were waived. Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Furthermore, we declare that there are no conflicts of interest that could compromise the objectivity and independence of this project. We have no personal, commercial, or financial relationships with entities that could directly or indirectly benefit from the results presented in this document.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}